{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
methyl salicylate
to a specific field?
Class (Stereo):
CHEMICAL (MIXED)
Etanterol (VAL 481), a phenethanolamine derivative, is a β2 adrenoceptor agonist that was undergoing phase II trials in Italy as a bronchodilator with Valeas.
Status:
Investigational
Source:
NCT01568229: Phase 2 Interventional Terminated Schizophrenia
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Tilapertin (also known as AMG 747) is a piperazineacetic acid derivative patented by Amgen Inc as glycine transporter-1 inhibitor useful for the treatment of negative symptoms of schizophrenia. Oral administration of AMG 747 dose-dependently increases cerebrospinal fluid(CSF) glycine concentration in rats. In humans, Tilapertin has linear pharmacokinetics, prolonged half-life, and acceptable safety and tolerability at multiple doses up to 60 mg daily dosing. Unfortunately, in clinical trials, Tilapertin failed to demonstrate superior efficacy compare antipsychotic therapy in clinically stable people with schizophrenia.
Class (Stereo):
CHEMICAL (ACHIRAL)
Citatepine is an antagonist of dopamine receptors. It attenuated dopamine-agonist induced behavioral stimulation (stereotypies in rats or climbing in mice). The compound displayed preferential action on hippocampal DA receptors as compared to the striatum. In addition, it shows antihistaminergic, antiserotonergic, anticholinergic and adrenolytic effects. The drug was investigated in the clinic for the treatment of schizophrenia. It was expected that this drug would show an antipsychotic efficacy in doses not causing extrapyramidal side-effects. This expectation has not been fulfilled.
Class (Stereo):
CHEMICAL (ACHIRAL)
Cinprazole (7110 MD) is an investigational benzimidazole derivative, discovered by Delalande S. A in 1972. The compound shows notable gastric antisecretory and antiulcer activity most likely due to a peripheral anti-acetylcholine action. Cinprazole also shows local anesthetic activity on rabbit cornea, and has no effect on the central nervous system in the mouse, rat and rabbit, or on the respiration in the rabbit.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Setazindol is an anorectic.
Class (Stereo):
CHEMICAL (ACHIRAL)
Domazoline is anticholinergic agent. It is antazoline derivative. Domazoline is antihistaminic, local vasoconstrictor and nasal decongestant. As a hair stiffener, it was used in depilatory preparations.
Status:
Investigational
Source:
NCT00083252: Phase 2 Interventional Completed Melanoma
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Talabostat is a prolineboronate ester derivative patented by Boehringer Ingelheim Pharmaceuticals, Inc. as an antineoplastic agent. Talabostat inhibits dipeptidyl peptidases, such as fibroblast activation protein (FAP), resulting in the stimulation of cytokine and chemokine production and specific T-cell immunity and T-cell dependent activity. Talabostat has been shown to cause caspase-1 activation and IL-1β induction in macrophages, which in turn causes upregulation of the cytokines and chemokines that characterize the responses to talabostat, both in vitro and in tumor-bearing mice. Talabostat may also stimulate the production of colony stimulating factors, such as granulocyte colony stimulating factor (G-CSF), resulting in the stimulation of hematopoiesis. In clinical trials, the combination of talabostat and cisplatin was well tolerated compared to historical data using cisplatin alone. The most frequent adverse events were nausea, vomiting, fatigue, anemia, edema, and constipation. Unfortunately was no evidence that Talabostat enhanced the clinical activity of other anticancer drugs and further development was discontinued.
Status:
Investigational
Source:
NCT00105521: Phase 3 Interventional Completed Parkinson's Disease
(2004)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Sarizotan (also known as EMD-128,130), a chromane derivative that was developed as a selective 5-HT1A receptor agonist and D2 receptor antagonist. Experiments on animal models have shown that the drug effectively suppressed levodopa-induced dyskinesia in primate and rodent models of Parkinson's disease, and tardive dyskinesia in a rodent model. Sarizotan participated in phase II/III clinical trials in the treatment of dyskinesia associated with the dopaminergic treatment of Parkinson's disease. However, further development for this disease was discontinued by Merk, because phase III did not confirm earlier Phase II findings. On July 14, 2015, Newron Pharmaceuticals, research, and development company focused on the novel central nervous system (CNS) and pain therapies, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to sarizotan for treatment of Rett syndrome. Besides, the drug now is an ongoing clinical trial phase II/III to investigate its the tolerability and efficacy in reducing respiratory abnormalities in Rett Syndrome.
Status:
Investigational
Source:
NCT00331721: Phase 2 Interventional Terminated Stroke
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Enecadin (NS 7 or ZK 228326) is a voltage-dependent sodium and calcium channel blocker. Enecadin is a neuroprotective agent demonstrated efficacy in animal models of ischemic injury of brain, spinal cord and retina. Enecadin was undergoing phase II development in stroke with PAION in Germany. Enecadin development has been discontinued.
Status:
Investigational
Source:
NCT00626418: Phase 2 Interventional Completed Restless Legs Syndrome
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Aplindore (DAB-452) is a small molecule that displays potent dopamine D2 receptor partial agonist activity in in vitro and in vivo assays and is predicted to have antipsychotic efficacy without motor side effects. Aplindore had been in phase II clinical trials for the treatment of Parkinson's disease and restless legs syndrome. Aplindore was generally well tolerated and there were no withdrawals due to adverse events and no serious adverse events.
